Share On Social!
Two new cholesterol drugs are too expensive, according a to a new report-Time Magazine informs.
The report, published by the Institute for Clinical and Economic Review looked at Repatha and Praluent, both recently approved by the FDA, and “weighed their benefits, including preventing heart attacks and death, against their prices.”
Repatha costs $14,100 a year and Praluent costs $14,600, but according to researchers the cost should be $3,615 to $4,811 a year.
“The price would actually have to drop even further, to an annual drug cost of $2,177, for the “total costs of these new drugs to come down to a level at which doctors and insurers would not have to try to limit patient use in some way to keep overall health care cost growth within bounds,” the researchers wrote in a statement.
Explore More:
Maternal & Child HealthBy The Numbers
20.7
percent
of Latino kids have obesity (compared to 11.7% of white kids)